Neurotoxicities from Cancer Immunotherapies

Dear Colleagues,

As you may know, the recent advent of cancer immunotherapy has revolutionized the prognosis of some advanced and refractory cancers, including melanoma and B-cell lymphomas. Regardless of their spectacular therapeutic results, cancer immunotherapies have been associated with a wide range of immune-related neurological complications, ranging from CNS dysfunction to neuromuscular disorders and myositis. Although neurologists, especially at academic cancer centers, have been learning how to diagnose and manage immune-related neurological adverse events, little is still known about rare clinical phenotypes and late-onset toxicities. The prediction and prevention of neurological toxicities is still in its infancy due to the lack of solid biomarkers, and the inadequate characterization of their pathophysiology hampers the implementation of individualized treatment approaches. Optimal treatment strategies in the case of corticosteroid resistance, as well as treatment duration, long-term prognosis and risk of relapse have not been clearly defined. This Special Issue invites original research articles and reviews addressing new clinical phenotypes, identifying novel biomarkers or offering insights on pathophysiology and personalized treatment strategies for immune-related neurological adverse events from cancer immunotherapies, including immune checkpoint inhibitors, CAR-T cells, drug-conjugated and bispecific antibodies. We welcome all contributions shedding light on this exciting area of research straddling between neuro-oncology and neuro-immunology.

Dr. Giulia Berzero
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer immunotherapy
• neurological toxicities
• immune checkpoint inhibitors
• CAR-T cells and bispecific antibodies
• cytokine release syndrome
• biomarkers
• personalized treatment